270 related articles for article (PubMed ID: 29296182)
1. MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy.
Xiong J; Wang D; Wei A; Ke N; Wang Y; Tang J; He S; Hu W; Liu X
Oncotarget; 2017 Dec; 8(64):107500-107512. PubMed ID: 29296182
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells.
Huang B; Wang J; Chen Q; Qu C; Zhang J; Chen E; Zhang Y; Wang Y; Ni L; Liang T
Am J Transl Res; 2019; 11(1):473-485. PubMed ID: 30788003
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
4. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J
Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
[TBL] [Abstract][Full Text] [Related]
6. Involvement of anti-tumor
Idichi T; Seki N; Kurahara H; Fukuhisa H; Toda H; Shimonosono M; Yamada Y; Arai T; Kita Y; Kijima Y; Mataki Y; Maemura K; Natsugoe S
Oncotarget; 2018 Jun; 9(48):28849-28865. PubMed ID: 29988949
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma.
Zhou L; Jia S; Ding G; Zhang M; Yu W; Wu Z; Cao L
J Cancer; 2019; 10(21):5031-5040. PubMed ID: 31602254
[TBL] [Abstract][Full Text] [Related]
8. The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the
Yonemori K; Seki N; Idichi T; Kurahara H; Osako Y; Koshizuka K; Arai T; Okato A; Kita Y; Arigami T; Mataki Y; Kijima Y; Maemura K; Natsugoe S
Oncotarget; 2017 Sep; 8(41):70097-70115. PubMed ID: 29050264
[TBL] [Abstract][Full Text] [Related]
9. Antagonistic Roles of the Tumor Suppressor miR-210-3p and Oncomucin MUC4 Forming a Negative Feedback Loop in Pancreatic Adenocarcinoma.
Boukrout N; Souidi M; Lahdaoui F; Duchêne B; Neve B; Coppin L; Leteurtre E; Torrisani J; Van Seuningen I; Jonckheere N
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944818
[TBL] [Abstract][Full Text] [Related]
10. Functional Significance and Therapeutic Potential of miR-15a Mimic in Pancreatic Ductal Adenocarcinoma.
Guo S; Fesler A; Huang W; Wang Y; Yang J; Wang X; Zheng Y; Hwang GR; Wang H; Ju J
Mol Ther Nucleic Acids; 2020 Mar; 19():228-239. PubMed ID: 31846800
[TBL] [Abstract][Full Text] [Related]
11. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN.
Xia X; Zhang K; Luo G; Cen G; Cao J; Huang K; Qiu Z
Am J Transl Res; 2017; 9(4):1886-1895. PubMed ID: 28469793
[TBL] [Abstract][Full Text] [Related]
13. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma.
Ling Q; Xu X; Ye P; Xie H; Gao F; Hu Q; Liu Z; Wei X; Röder C; Trauzold A; Kalthoff H; Zheng S
Oncotarget; 2017 Feb; 8(9):15159-15167. PubMed ID: 28122349
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-Mediated Therapy with miR-198 Sensitizes Pancreatic Cancer to Gemcitabine Treatment through Downregulation of VCP-Mediated Autophagy.
Marin-Muller C; Li D; Lü JM; Liang Z; Vega-Martínez O; Crawford SE; Estes MK; Fisher WE; Chen C; Yao Q
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631252
[TBL] [Abstract][Full Text] [Related]
15. Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC.
Shao H; Zhang Y; Yan J; Ban X; Fan X; Chang X; Lu Z; Wu Y; Zong L; Mo S; Yu S; Chen J
Onco Targets Ther; 2021; 14():2163-2175. PubMed ID: 33790579
[TBL] [Abstract][Full Text] [Related]
16. miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy.
Tan S; Shi H; Ba M; Lin S; Tang H; Zeng X; Zhang X
Int J Mol Med; 2016 Apr; 37(4):1030-8. PubMed ID: 26935807
[TBL] [Abstract][Full Text] [Related]
17. MiR-24-3p Inhibits the Progression of Pancreatic Ductal Adenocarcinoma Through LAMB3 Downregulation.
Huang W; Gu J; Tao T; Zhang J; Wang H; Fan Y
Front Oncol; 2019; 9():1499. PubMed ID: 32039003
[TBL] [Abstract][Full Text] [Related]
18. MiR-193a-3p inhibits pancreatic ductal adenocarcinoma cell proliferation by targeting CCND1.
Chen ZM; Yu Q; Chen G; Tang RX; Luo DZ; Dang YW; Wei DM
Cancer Manag Res; 2019; 11():4825-4837. PubMed ID: 31213904
[No Abstract] [Full Text] [Related]
19. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1.
Zhou L; Zhang WG; Wang DS; Tao KS; Song WJ; Dou KF
Oncol Rep; 2014 Oct; 32(4):1734-40. PubMed ID: 25109303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
